Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus platinum-based chemotherapy with or without low-dose intestinal irradiation for advanced NSCLC
ChiCTR2600119639Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600119639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119639.